- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Telferscot to Distribute Equity in Seven New Companies to TFS Shareholders
Telferscot Resources Inc. (CSE:TFS) (“Telferscot” or the “Company”) is pleased to announce that the Company has received confirmation from the Canadian Securities Exchange of approval of the listing of the common shares of Canntab Therapeutics Limited (“Canntab”) subject to completion of the transactions as described in the listing statement and completion of any and all outstanding CSE documentation and fee payments.
Telferscot Resources issued the press release below on April 5, 2018:
Telferscot Resources Inc. (CSE:TFS) (“Telferscot” or the “Company“) issues correction to April 3, 2018 release regarding figures for the shares distributed to Telferscot shareholders under the Company’s Plan of Arrangement.
Please see the following CORRECTED number of shares to be received by shareholders of Telferscot:
For every 1,000 shares of Telferscot owned as of the Record Date (above), Telferscot shareholders will receive:
- 100 shares of SpinCo #1
- 20 shares of SpinCo #2 **
- 20 shares of SpinCo #3 **
- 20 shares of SpinCo #4 **
- 100 shares of SpinCo #5
- 20 shares of SpinCo #6 **
- 200 shares of SpinCo #7
** Figures have been corrected, due to a typographical error, not due to any changes in the Company’s plans.
None of these companies are currently listed for trading on any exchange and as such, the shares are not currently readily saleable. It is the intention of six of the seven companies to complete the planned acquisitions of business as outlined in the Management Information Circular dated March 1, 2018 and available at www.tfs-poa.com. The seventh company, SpinCo #7, will continue to pursue the Company’s legal action against Auxico Resources Canada Inc.
For complete information on the Plan of Arrangement and the acquisition to Canntab Therapeutics, investors and shareholders are encouraged to go to www.tfs-poa.com. Investors can sign up there to receive investor communications on the activities of Canntab as well as plans and developments in each of the new entities to be distributed to shareholders.
About Telferscot Resources Inc.
Telferscot Resources Inc. is a Canadian company listed on the CSE under ticker symbol TFS. For further information and access to the Company’s public disclosure record please consult SEDAR at www.sedar.com or the Canadian Securities Exchange at www.thecse.com.
Click here to connect with Canntab Therapeutics Limited for an Investor Presentation
Original press release published on April 4, 2018:
Telferscot Resources Inc. (CSE:TFS) (“Telferscot” or the “Company”) is pleased to announce that the Company has received confirmation from the Canadian Securities Exchange of approval of the listing of the common shares of Canntab Therapeutics Limited (“Canntab”) subject to completion of the transactions as described in the listing statement and completion of any and all outstanding CSE documentation and fee payments.
Additionally, the Company is pleased to inform shareholders and investors that the shareholders of Canntab have approved the acquisition of Canntab by Telferscot as detailed in the Company’s Management Information Circular.
It is anticipated that the transaction will close on or about April 9, 2018. At which point, Telferscot shares will be exchanged for new shares of Canntab on a ratio of 1 new Canntab share for every 200 current Telferscot shares.
Following closing of the transaction and subject to any approvals by the Canadian Securities Exchange and Regulators, Canntab shares will commence trading on the CSE under the trading symbol: “PILL”
For information on the transaction as well as the Telferscot Plan of Arrangement — the distribution of new company shares to Telferscot shareholders, please go to www.tfs-poa.com. Investors can sign up there to receive news and investor communications on the activities of Canntab as well as plans and developments in each of the new entities to be distributed to shareholders.
About Canntab Therapeutics Limited
Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extracted from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab’s mission is to put the “Medical” into medicinal cannabis!
About Telferscot Resources Inc.
Telferscot Resources Inc. is a Canadian company listed on the CSE under ticker symbol TFS. For further information and access to the Company’s public disclosure record please consult SEDAR at www.sedar.com or the Canadian Securities Exchange at www.thecse.com.
Click here to connect with Canntab Therapeutics Limited for an Investor Presentation
Source: www.newsfilecorp.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.